Answers are grounded in this paper and cite their sources.
Residual LDLR expression in HoFH is a major determinant of LDL-C levels and seems to drive their individual response to evolocumab.
No takes yet. Share an insight, caveat, or question.
Thedrez et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: